MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34

^th

Annual Roth Conference.

Management is scheduled to present on Tuesday, March 15, 2022 at 10:00 a.m. PT / 1:00 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at:

www.iridex.com

.

About Iridex


Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse

^®

technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit

www.iridex.com

.

Investor Relations Contact:


Leigh Salvo

(415) 937-5404


[email protected]